Xue Bai
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 47
- Cutaneous Melanoma Detection and Management 38
- CAR-T cell therapy research 36
- Immunology top 10%
- Immunotherapy and Immune Responses 21
- Cancer Research top 10%
-
- Melanoma and MAPK Pathways 34
-
- Renal cell carcinoma treatment 8
-
- Virus-based gene therapy research 11
-
- Bladder and Urothelial Cancer Treatments 9
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Journal of Clinical Oncology (48 papers)Cancer Research (1 paper)Scientific Reports (1 paper)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Xue Bai
133 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 115
- Oncology 877
- Immunology 318
- Cancer Research 173
- Molecular Biology 620
- Pulmonary and Respiratory Medicine 187
Countries citing papers authored by Xue Bai
This map shows the geographic impact of Xue Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue Bai more than expected).
Fields of papers citing papers by Xue Bai
This network shows the impact of papers produced by Xue Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue Bai. The network helps show where Xue Bai may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xue Bai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 1 | |
| 9 | 2024 | 8 | |
| 10 | 2024 | 2 | |
| 11 | 2023 | 5 | |
| 12 | 2023 | 2 | |
| 13 | 2022 | 19 | |
| 14 | 2022 | 38 | |
| 15 | 2022 | 33 | |
| 16 | 2022 | 20 | |
| 17 | 2021 | 8 | |
| 18 | 2021 | 36 | |
| 19 | 2021 | 1 | |
| 20 | 2017 | 72 |
About Xue Bai
Xue Bai is a scholar working on Oncology, Cancer Research and Immunology, having authored 148 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (47 papers), Cutaneous Melanoma Detection and Management (38 papers), CAR-T cell therapy research (36 papers), Melanoma and MAPK Pathways (34 papers), Immunotherapy and Immune Responses (21 papers), Virus-based gene therapy research (11 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Renal cell carcinoma treatment (8 papers). The work is most often cited by research in Oncology (877 citations), Immunology (318 citations) and Cancer Research (173 citations). Xue Bai has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Lu Si, Bin Lian, Li Zhou, Xinan Sheng, Chuanliang Cui, Xieqiao Yan, Jun Guo, Bixia Tang, Keith T. Flaherty and Zhihong Chi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.